BioLineRx Corp (BLRX) - שווי פעילות לרווח לפני ריבית, מסים ופחת
The BioLineRx Ltd. (BLRX) business model is based on the promotion of Aphexda, with the primary growth drivers being the reach of transplant centers and trials for the treatment of pancreatic tumors. The product's integration into hematological practice accelerates stem cell collection, establishing the method as an industry standard. The market trend reflects an EV/EBITDA value of 0.00. Stable management is successfully expanding insurance reimbursements in the US, strengthening shareholder confidence.
BLRX (biolinerx.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Fundamental asset screening requires analyzing business value relative to its ability to generate earnings before interest, taxes, depreciation, and amortization. An EV/EBITDA multiple valuation compares the total capitalization of BioLineRx Ltd. (BLRX) with its operating cash flow, where stable figures confirm the company's resilience amid the commercialization of its stem cell drug and the minimization of liquidity risks.
